Le Lézard
Classified in: Science and technology, Business, Covid-19 virus
Subjects: EARNINGS, Conference Call, Webcast, Advisory

DXC Technology to Report Third Quarter 2024 Results on Thursday, February 1, 2024


DXC Technology (NYSE: DXC) today announced that it will release financial results for the third quarter of fiscal year 2024 on Thursday, February 1, 2024, at approximately 4:15 p.m. Eastern Standard Time (EST).

DXC Technology senior management will host a conference call and webcast on the same day at 5:00 p.m. EST. The dial-in number for domestic callers is 888-330-2455. Callers who reside outside of the United States should dial +1-240-789-2717. The passcode for all participants is 4164760. The webcast audio and any presentation slides will be available through a link posted on DXC Technology's Investor Relations website.

A replay of the conference call will be available until 11:59 PM EST on February 8, 2024, at 800-770-2030 for domestic callers and at +1-647-362-9199 for international callers. The replay passcode is 4164760. A transcript of the conference call will be posted on DXC Technology's Investor Relations website.

About DXC Technology

DXC Technology (NYSE: DXC) helps global companies run their mission-critical systems and operations while modernizing IT, optimizing data architectures, and ensuring security and scalability across public, private, and hybrid clouds. The world's largest companies and public sector organizations trust DXC to deploy services to drive new levels of performance, competitiveness, and customer experience across their IT estates. Learn more about how we deliver excellence for our customers and colleagues at DXC.com.

Forward-Looking Statements

All statements in this press release that do not directly and exclusively relate to historical facts constitute "forward-looking statements." These statements represent current expectations and beliefs, and no assurance can be given that the results described in such statements will be achieved. Such statements are subject to numerous assumptions, risks, uncertainties and other factors that could cause actual results to differ materially from those described in such statements, many of which are outside of our control. Furthermore, many of these risks and uncertainties are currently amplified by and may continue to be amplified by or may, in the future, be amplified by, the ongoing coronavirus disease 2019 ("COVID-19") pandemic and the impact of varying private and governmental responses that affect our customers, employees, vendors and the economies and communities where they operate. For a written description of these factors, see the section titled "Risk Factors" in DXC's Annual Report on Form 10-K for the fiscal year ended March 31, 2023, and any updating information in subsequent SEC filings, including DXC's upcoming Quarterly Report on Form 10-Q for the quarterly period ended December 31, 2023. No assurance can be given that any goal or plan set forth in any forward-looking statement can or will be achieved, and readers are cautioned not to place undue reliance on such statements which speak only as of the date they are made. We do not undertake any obligation to update or release any revisions to any forward-looking statement or to report any events or circumstances after the date of this presentation or to reflect the occurrence of unanticipated events, except as required by law.

Category: Investor Relations


These press releases may also interest you

at 13:00
In an industry where success often hinges on the backing of major labels, Boston-born hip-hop artist and MIH Universal founder Matt Corman has defied the odds. Grossing over $1 million from digital streaming alone, Corman has risen to the top 1% of...

at 11:45
The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Humana Inc. ("Humana" or "the Company") for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5...

at 11:30
NeuroCytonix, Inc., today announced that on May 27, 2024, its subsidiary NeuroCytonix Mexico received a regulatory approval letter from the ethical, scientific, and safety committees of Hospital La Mision in Monterrey, Mexico, to launch a clinical...

at 11:00
States with high rates of COVID-19 vaccination saw more pediatric asthma patients get a break from their symptoms, according to new research published today in JAMA Network Open by leaders from Nemours Children's Health and Endeavor Health....

at 11:00
Art's Way Manufacturing Co., Inc. (the "Company"), a diversified manufacturer and distributor of equipment serving agricultural and research needs, announces its financial results for the second quarter of fiscal 2024 and six months ended...

at 10:35
The "Indonesia Construction Industry Databook Series - Market Size & Forecast by Value and Volume (area and units), Q1 2024 Update" report has been added to ResearchAndMarkets.com's offering. The construction industry in Indonesia is expected to...



News published on and distributed by: